@article{d4b85dce50484e168e857242cfb38340,
title = "ABSORB IV: will the low rate of scaffold thrombosis persist? – Authors' reply",
author = "Stone, {Gregg W.} and Ellis, {Stephen G.} and Kereiakes, {Dean J.}",
note = "Funding Information: GWS reports grants from Abbott to the Cardiovascular Research Foundation, during the conduct of the study; personal fees from Terumo, Medical Development Technologies, Amaranth, Sirtex, Abiomed, Claret, Backbeat, Shockwave, Valfix, TherOx, Reva, Vascular Dynamics, Robocath, HeartFlow, Gore, Ablative Solutions, Matrizyme, Miracor, Neovasc, and V-wave; personal fees and stock options in SpectraWave, Ancora, and Qool Therapeutics; stock options in Biostar family of funds, MedFocus family of funds, Cagent, Applied Therapeutics, and Caliber, outside of the submitted work. Columbia University, GWS's employer, receives royalties from Abbott Laboratories for sale of the MitraClip. SGE reports grants and consulting fees from Abbott Vascular, outside of the submitted work. DJK reports receiving grants for research from Abbott Vascular, and consulting fees and honoraria from Abbott Vascular, Boston Scientific, Caliber Therapeutics/Orchestra Biomed, Micell Technologies, and SINO Medical Sciences Technologies.",
year = "2019",
month = jun,
day = "15",
doi = "10.1016/S0140-6736(19)30687-7",
language = "English",
volume = "393",
pages = "2392--2393",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Ltd.",
number = "10189",
}